Suggested remit: To appraise the clinical and cost effectiveness of oral paclitaxel with encequidar within its marketing authorisation for treating advanced breast cancer.
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Rationale:
- DHSC referral received
- Process:
- TA
- ID number:
- 5111
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 February 2023 | Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 07 October 2022 | Note added to the project documents |
| 08 August 2022 - 06 September 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 07 July 2022 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual